Hematotoxicity
At TAD we work to assess erythrocyte fragility for personalized medicine
A novel, quantitative assay using humanized mice that
precisely measures the susceptibility to hemolysis in
circulation distinguishing between:
Basal structural
susceptibility
Pathology-induced
hemolysis
Drug-induced
hemolysis
A new standard in hematotoxicity profiling
ADVANTAGES OF THE MODEL:
Combining industrial quality in animal models with the power of TADmaps® mathematical models.
· Long half-life of human erythrocytes (>20 days) CV < 2 % intragroup
· Feasible linking PK/TK in the same experimental individuals
· Adaptive experimental protocols
· Individual statistics-No need of placebo controls
· Quantitative discrimination of intrinsic and drug-induced hemotox/hemolysis
· Fully pharmacologically validated
This makes it the only available platform that enables accurate and reproducible evaluation of hematotoxicity in a human-relevant context.
